Jeffrey T L Smith - Jan 6, 2025 Form 4 Insider Report for Zymeworks Inc. (ZYME)

Role
EVP & Chief Medical Officer
Signature
/s/ Daniel Dex, Attorney-in-Fact
Stock symbol
ZYME
Transactions as of
Jan 6, 2025
Transactions value $
-$165,807
Form type
4
Date filed
1/6/2025, 08:19 PM
Previous filing
Jan 8, 2024
Next filing
Jan 10, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZYME Common Stock Options Exercise $0 +20K $0.00 20K Jan 6, 2025 Direct F1
transaction ZYME Common Stock Sale -$166K -11.1K -55.55% $14.92 8.89K Jan 6, 2025 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZYME Restricted Stock Unit Options Exercise $0 -20K -33.33% $0.00 40K Jan 6, 2025 Common Stock 20K Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on January 5, 2024.
F2 Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory "sell to cover" provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.44 to $15.14, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F4 Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.
F5 The RSUS were granted on January 5, 2024 and vest in three equal annual installments beginning on the first anniversary of January 5, 2024.